These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 10530584)
41. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486 [TBL] [Abstract][Full Text] [Related]
42. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. Dorman SE; Goldberg S; Stout JE; Muzanyi G; Johnson JL; Weiner M; Bozeman L; Heilig CM; Feng PJ; Moro R; Narita M; Nahid P; Ray S; Bates E; Haile B; Nuermberger EL; Vernon A; Schluger NW; J Infect Dis; 2012 Oct; 206(7):1030-40. PubMed ID: 22850121 [TBL] [Abstract][Full Text] [Related]
43. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Vernon A; Burman W; Benator D; Khan A; Bozeman L Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410 [TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Peloquin CA; Namdar R; Singleton MD; Nix DE Chest; 1999 Jan; 115(1):12-8. PubMed ID: 9925057 [TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers. Medellín-Garibay SE; Milán-Segovia Rdel C; Magaña-Aquino M; Portales-Pérez DP; Romano-Moreno S J Pharm Pharmacol; 2014 Oct; 66(10):1421-8. PubMed ID: 24841364 [TBL] [Abstract][Full Text] [Related]
46. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Tam CM; Chan SL; Lam CW; Dickinson JM; Mitchison DA Int J Tuberc Lung Dis; 1997 Oct; 1(5):411-6. PubMed ID: 9441094 [TBL] [Abstract][Full Text] [Related]
47. Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis. Dian S; Yunivita V; Ganiem AR; Pramaesya T; Chaidir L; Wahyudi K; Achmad TH; Colbers A; Te Brake L; van Crevel R; Ruslami R; Aarnoutse R Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224533 [TBL] [Abstract][Full Text] [Related]
48. Comparison of biological and chemical assays for the quantitation of rifapentine in human plasma. Kenny MT; Reynolds DL; Brackman MA; Dulworth JK Diagn Microbiol Infect Dis; 1997 Apr; 27(4):107-11. PubMed ID: 9154405 [TBL] [Abstract][Full Text] [Related]
49. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. Conte JE; Golden JA; Kipps JE; Lin ET; Zurlinden E Clin Pharmacokinet; 2004; 43(6):395-404. PubMed ID: 15086276 [TBL] [Abstract][Full Text] [Related]
50. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations. Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981 [TBL] [Abstract][Full Text] [Related]
51. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. Rastogi N; Goh KS; Berchel M; Bryskier A J Antimicrob Chemother; 2000 Oct; 46(4):565-70. PubMed ID: 11020253 [TBL] [Abstract][Full Text] [Related]
52. The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO. Panchagnula R; Kaur KJ; Singh I; Kaul CL Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S336-42; discussion S351-2. PubMed ID: 10593714 [TBL] [Abstract][Full Text] [Related]
54. Rifapentine for the treatment of tuberculosis: is it all it can be? Gordin FM Am J Respir Crit Care Med; 2004 Jun; 169(11):1176-7. PubMed ID: 15161608 [No Abstract] [Full Text] [Related]
55. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. Svensson EM; Murray S; Karlsson MO; Dooley KE J Antimicrob Chemother; 2015 Apr; 70(4):1106-14. PubMed ID: 25535219 [TBL] [Abstract][Full Text] [Related]
56. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936 [TBL] [Abstract][Full Text] [Related]
58. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers. Mahatthanatrakul W; Nontaput T; Ridtitid W; Wongnawa M; Sunbhanich M J Clin Pharm Ther; 2007 Apr; 32(2):161-7. PubMed ID: 17381666 [TBL] [Abstract][Full Text] [Related]
59. Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure. Jayakumar A; Savic RM; Everett CK; Benator D; Alland D; Heilig CM; Weiner M; Friedrich SO; Martinson NA; Kerrigan A; Zamudio C; Goldberg SV; Whitworth WC; Davis JL; Nahid P J Clin Microbiol; 2016 Dec; 54(12):3028-3033. PubMed ID: 27733634 [TBL] [Abstract][Full Text] [Related]
60. Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. Deng S; Chen XP; Cao D; Yin T; Dai ZY; Luo J; Tang L; Li YJ Clin Ther; 2009 Jun; 31(6):1256-63. PubMed ID: 19695392 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]